See more : The Connecticut Light and Power Company (CNLTN) Income Statement Analysis – Financial Results
Complete financial analysis of Johnson & Johnson (JNJ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Johnson & Johnson, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) Income Statement Analysis – Financial Results
- NeuroScientific Biopharmaceuticals Limited (NSB.AX) Income Statement Analysis – Financial Results
- Dalrymple Bay Infrastructure Limited (DBI.AX) Income Statement Analysis – Financial Results
- Jia Group Holdings Limited (8519.HK) Income Statement Analysis – Financial Results
- Netronix, Inc. (6143.TWO) Income Statement Analysis – Financial Results
Johnson & Johnson (JNJ)
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B | 71.31B | 67.22B | 65.03B | 61.59B | 61.90B | 63.75B | 61.10B | 53.32B | 50.51B | 47.35B | 41.86B | 36.30B | 33.00B | 29.14B | 27.47B | 23.66B | 22.63B | 21.62B | 18.84B | 15.73B | 14.14B | 13.75B | 12.45B | 11.23B | 9.76B | 9.00B | 8.01B | 7.00B | 6.42B |
| Cost of Revenue | 26.55B | 24.60B | 23.40B | 28.43B | 27.56B | 27.09B | 25.35B | 21.69B | 21.54B | 22.75B | 22.34B | 21.66B | 20.36B | 18.79B | 18.45B | 18.51B | 17.75B | 15.06B | 13.95B | 13.42B | 12.18B | 10.45B | 9.54B | 7.35B | 7.00B | 6.19B | 6.09B | 6.01B | 5.38B | 4.58B | 4.17B | 4.12B | 3.71B | 3.46B | 3.07B | 2.90B | 2.60B | 2.35B | 2.34B |
| Gross Profit | 58.61B | 55.39B | 55.34B | 54.16B | 54.50B | 54.49B | 51.10B | 50.21B | 48.54B | 51.59B | 48.97B | 45.57B | 44.67B | 42.80B | 43.45B | 45.24B | 43.34B | 38.27B | 36.56B | 33.93B | 29.69B | 25.85B | 23.47B | 21.79B | 20.47B | 17.47B | 16.54B | 15.61B | 13.46B | 11.16B | 9.96B | 9.64B | 8.74B | 7.77B | 6.69B | 6.10B | 5.41B | 4.65B | 4.08B |
| Gross Profit Ratio | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.84% | 69.84% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% | 71.76% | 72.38% | 71.65% | 70.91% | 71.22% | 71.11% | 74.79% | 74.53% | 73.83% | 73.11% | 72.21% | 71.46% | 70.92% | 70.48% | 70.06% | 70.19% | 69.17% | 68.58% | 67.77% | 67.52% | 66.37% | 63.50% |
| Research & Development | 15.05B | 14.14B | 14.28B | 12.34B | 11.36B | 10.78B | 10.55B | 9.10B | 9.05B | 8.49B | 8.18B | 7.67B | 7.55B | 6.84B | 7.17B | 7.76B | 7.68B | 7.13B | 6.31B | 5.20B | 4.68B | 3.96B | 3.59B | 2.93B | 2.60B | 2.27B | 2.14B | 0.00 | 0.00 | 1.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.11B | 19.05B | 20.12B | 22.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.11B | 19.05B | 20.12B | 22.08B | 22.18B | 22.54B | 21.42B | 19.95B | 21.20B | 21.95B | 21.83B | 20.87B | 20.97B | 19.42B | 19.80B | 21.49B | 20.45B | 17.43B | 16.88B | 15.86B | 14.13B | 12.22B | 11.99B | 10.88B | 10.50B | 8.91B | 8.72B | 10.30B | 9.10B | 6.35B | 6.95B | 6.80B | 6.08B | 5.30B | 4.62B | 4.30B | 3.85B | 3.39B | 2.99B |
| Other Expenses | 0.00 | 500.00M | -526.00M | -2.90B | -2.53B | -1.41B | -183.00M | -484.00M | 2.06B | 70.00M | -2.50B | -1.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.56B | 33.18B | 34.40B | 34.42B | 33.53B | 33.32B | 31.97B | 29.04B | 30.25B | 30.45B | 30.01B | 28.53B | 28.52B | 26.27B | 26.97B | 29.25B | 28.13B | 24.56B | 23.19B | 21.06B | 18.82B | 16.17B | 15.58B | 15.32B | 14.55B | 12.42B | 11.92B | 11.31B | 9.95B | 8.35B | 7.57B | 7.36B | 6.57B | 5.78B | 5.03B | 4.70B | 4.20B | 3.66B | 3.24B |
| Cost & Expenses | 61.81B | 57.78B | 57.80B | 62.85B | 61.09B | 60.41B | 57.33B | 50.73B | 51.79B | 53.19B | 52.36B | 50.19B | 48.88B | 45.06B | 45.42B | 47.76B | 45.88B | 39.62B | 37.14B | 34.49B | 30.99B | 26.62B | 25.12B | 22.66B | 21.55B | 18.61B | 18.01B | 17.32B | 15.33B | 12.93B | 11.74B | 11.48B | 10.28B | 9.24B | 8.10B | 7.60B | 6.80B | 6.02B | 5.58B |
| Interest Income | 1.26B | 490.00M | 53.00M | 111.00M | 357.00M | 611.00M | 385.00M | 368.00M | 128.00M | 67.00M | 74.00M | 64.00M | 91.00M | 107.00M | 90.00M | 361.00M | 452.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 772.00M | 276.00M | 183.00M | 201.00M | 318.00M | 1.01B | 934.00M | 726.00M | 552.00M | 533.00M | 482.00M | 532.00M | 571.00M | 348.00M | 451.00M | 435.00M | 296.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B | 3.75B | 3.90B | 4.10B | 3.67B | 3.16B | 2.94B | 2.77B | 2.83B | 2.78B | 2.18B | 2.09B | 2.12B | 1.87B | 1.66B | 1.61B | 1.52B | 1.44B | 1.25B | 1.07B | 1.01B | 857.00M | 724.00M | 617.00M | 560.00M | 493.00M | 474.00M | 414.00M | 391.00M | 356.00M | 275.20M | 250.50M |
| EBITDA | 23.73B | 27.17B | 30.93B | 27.50B | 28.27B | 28.10B | 24.54B | 24.92B | 22.12B | 25.03B | 23.16B | 17.96B | 16.05B | 20.35B | 18.96B | 20.20B | 16.36B | 15.77B | 15.61B | 15.02B | 13.27B | 11.82B | 9.78B | 8.08B | 7.59B | 6.96B | 5.62B | 5.46B | 4.42B | 3.58B | 2.93B | 2.78B | 2.65B | 2.63B | 2.08B | 1.70B | 1.47B | 1.79B | 985.40M |
| EBITDA Ratio | 27.86% | 37.71% | 35.38% | 29.27% | 26.96% | 27.64% | 25.95% | 30.16% | 27.15% | 28.68% | 27.40% | 27.07% | 29.93% | 26.84% | 27.51% | 27.84% | 32.86% | 29.58% | 30.91% | 31.72% | 31.71% | 32.57% | 29.63% | 27.73% | 27.64% | 29.41% | 24.81% | 25.24% | 23.45% | 22.72% | 20.73% | 20.24% | 21.32% | 23.45% | 21.33% | 18.88% | 18.29% | 25.50% | 15.35% |
| Operating Income | 23.41B | 23.19B | 20.47B | 16.95B | 15.12B | 15.62B | 14.20B | 17.93B | 15.28B | 17.42B | 15.43B | 14.53B | 16.31B | 13.59B | 14.26B | 14.92B | 17.30B | 13.60B | 13.52B | 12.90B | 11.40B | 10.16B | 8.18B | 6.57B | 6.15B | 5.71B | 4.55B | 4.45B | 3.56B | 2.85B | 2.31B | 2.22B | 2.16B | 2.16B | 1.67B | 1.31B | 1.11B | 1.51B | 734.90M |
| Operating Income Ratio | 27.49% | 28.99% | 26.00% | 20.52% | 18.42% | 19.15% | 18.57% | 24.94% | 21.80% | 23.44% | 21.64% | 21.61% | 25.08% | 22.06% | 23.03% | 23.40% | 28.31% | 25.50% | 26.76% | 27.24% | 27.24% | 27.99% | 24.77% | 22.53% | 22.38% | 24.14% | 20.10% | 20.57% | 18.90% | 18.12% | 16.37% | 16.16% | 17.36% | 19.23% | 17.09% | 14.53% | 13.84% | 21.57% | 11.44% |
| Total Other Income/Expenses | -8.35B | -2.85B | -1.77B | -3.24B | 2.21B | 2.38B | -1.22B | -1.09B | 907.00M | -574.00M | 38.00M | -3.26B | -3.79B | 420.00M | -908.00M | 760.00M | -1.93B | 990.00M | 137.00M | 482.00M | -563.00M | -387.00M | -277.00M | 303.00M | -108.00M | -846.00M | -46.00M | -270.00M | -194.00M | -126.00M | -62.00M | -70.00M | -126.00M | -369.00M | -147.00M | -8.00M | -16.00M | -592.80M | 164.30M |
| Income Before Tax | 15.06B | 19.36B | 19.18B | 16.50B | 17.33B | 18.00B | 17.67B | 19.80B | 19.20B | 20.56B | 15.47B | 13.78B | 12.36B | 16.95B | 15.76B | 16.93B | 13.28B | 14.59B | 13.66B | 12.84B | 10.31B | 9.29B | 7.90B | 6.62B | 5.75B | 4.27B | 4.58B | 4.03B | 3.32B | 2.68B | 2.33B | 2.21B | 2.04B | 1.62B | 1.51B | 1.40B | 1.19B | 390.80M | 899.20M |
| Income Before Tax Ratio | 17.69% | 24.20% | 24.36% | 19.98% | 21.12% | 22.06% | 23.12% | 27.55% | 27.39% | 27.66% | 21.69% | 20.49% | 19.01% | 27.52% | 25.45% | 26.56% | 21.74% | 27.36% | 27.03% | 27.11% | 24.62% | 25.60% | 23.93% | 22.73% | 20.94% | 18.05% | 20.22% | 18.65% | 17.60% | 17.04% | 16.49% | 16.05% | 16.37% | 14.45% | 15.52% | 15.51% | 14.89% | 5.58% | 14.00% |
| Income Tax Expense | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B | 2.70B | 16.37B | 3.26B | 3.79B | 4.24B | 1.64B | 3.26B | 2.69B | 3.61B | 3.49B | 3.98B | 2.71B | 3.53B | 3.25B | 4.33B | 3.11B | 2.69B | 2.23B | 1.82B | 1.59B | 1.21B | 1.27B | 1.15B | 914.00M | 675.00M | 545.00M | 582.00M | 577.00M | 480.00M | 432.00M | 422.00M | 360.00M | 61.30M | 285.50M |
| Net Income | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B | 13.83B | 10.85B | 9.67B | 13.33B | 12.27B | 12.95B | 10.58B | 11.05B | 10.41B | 8.51B | 7.20B | 6.60B | 5.67B | 4.80B | 4.17B | 3.06B | 3.30B | 2.89B | 2.40B | 2.01B | 1.79B | 1.03B | 1.46B | 1.14B | 1.08B | 974.00M | 833.00M | 329.50M | 613.70M |
| Net Income Ratio | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% | 20.73% | 20.61% | 17.97% | 17.19% | 18.17% | 17.17% | 16.47% | 15.17% | 12.93% | 14.60% | 13.35% | 12.75% | 12.75% | 12.64% | 7.49% | 11.74% | 10.18% | 11.09% | 10.82% | 10.40% | 4.71% | 9.56% |
| EPS | 13.88 | 6.86 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 | 4.90 | 3.91 | 3.54 | 4.86 | 4.45 | 4.67 | 3.67 | 3.76 | 3.38 | 2.75 | 2.42 | 2.20 | 1.87 | 1.65 | 1.43 | 1.08 | 1.24 | 1.09 | 0.93 | 0.78 | 0.69 | 0.17 | 0.55 | 0.43 | 0.41 | 0.36 | 0.31 | 0.12 | 0.21 |
| EPS Diluted | 13.73 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 | 5.48 | 5.70 | 4.81 | 3.86 | 3.49 | 4.78 | 4.40 | 4.57 | 3.63 | 3.73 | 3.35 | 2.74 | 2.29 | 2.16 | 1.84 | 1.61 | 1.39 | 1.06 | 1.21 | 1.09 | 0.93 | 0.78 | 0.68 | 0.16 | 0.54 | 0.43 | 0.40 | 0.35 | 0.31 | 0.12 | 0.21 |
| Weighted Avg Shares Out | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B | 2.66B | 2.68B | 2.71B | 2.76B | 2.78B | 2.82B | 2.78B | 2.72B | 2.74B | 2.76B | 2.81B | 2.88B | 2.94B | 2.98B | 2.97B | 2.97B | 3.00B | 3.03B | 2.99B | 2.99B | 2.78B | 2.67B | 2.66B | 2.58B | 2.57B | 2.61B | 2.63B | 2.66B | 2.66B | 2.67B | 2.74B | 2.73B | 2.75B | 2.92B |
| Weighted Avg Shares Out (Dil) | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B | 2.81B | 2.86B | 2.88B | 2.81B | 2.78B | 2.79B | 2.79B | 2.84B | 2.91B | 2.96B | 3.00B | 2.99B | 3.14B | 3.05B | 3.08B | 3.10B | 3.07B | 2.83B | 2.74B | 2.73B | 2.58B | 2.61B | 2.63B | 2.63B | 2.71B | 2.69B | 2.71B | 2.78B | 2.73B | 2.75B | 2.92B |
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief...
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
J&J CFO Wolk on Product Pipeline, Strategy and Talc Lawsuit
Johnson & Johnson CFO Joseph Wolk discusses the company's product pipeline, acquisition strategy and the latest on the talc baby powder lawsuit on "Bloomberg Open Interest." J&J reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine Darzalex.
How to play biotech stocks: Johnson & Johnson, Pfizer
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says...
Blue Chip Faces Off With Resistance After Earnings
Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance.
Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal Costs
Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions in one-time expenses like legal costs and acquisitions.
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall...
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave enhances Johnson & Johnson's MedTech business, opening new opportunities...
J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticals
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, R&D investment, growth outlook, state of the company's talc settlement, and more.
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.66 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports